A phase 1 study of safety and immunogenicity of E. coli-derived recombinant protective antigen (rPA), a new anthrax vaccine administered by the intramuscular (IM) route in healthy adults
Latest Information Update: 17 Oct 2018
At a glance
- Drugs Anthrax vaccine (Primary)
- Indications Anthrax
- Focus Adverse reactions
- 30 Jan 2007 Status changed from recruiting
- 11 Nov 2005 New trial record.